Therapy Areas: AIDS & HIV
Five-year US study highlights long-term effectiveness of ViiV Healthcare's Cabenuva
21 October 2026 - Specialist HIV company ViiV Healthcare, majority owned by GSK (LON:GSK), with Shionogi as a shareholder, on Wednesday reported five-year real-world data from the US OPERA observation...
Continuity Biosciences awarded Gates Foundation grant to advance ultra-long-acting implant for HIV prevention
15 October 2026 - Clinical-stage biotechnology company Continuity Biosciences LLC announced on Wednesday that it has been awarded a grant of up to USD9.6m from the Gates Foundation to advance a subcut...
Tolerance Bio licenses clinical-stage IL-7 therapy from NeoImmuneTech
19 August 2026 - Tolerance Bio Inc, a biotechnology company focused on preserving, regenerating and modulating thymic function to address immune diseases and extend healthspan, announced on Wednesday ...
Replicate Bioscience awarded Gates Foundation grant to advance srRNA vaccine candidates for TB
22 June 2026 - Replicate Bioscience, a clinical-stage company developing novel self-replicating RNA (srRNA) technology for applications across infectious disease, immunology, and other therapeutic are...
Breckenridge Pharmaceutical launches Pomalidomide Capsules in US market
3 March 2026 - Breckenridge Pharmaceutical Inc, the US subsidiary of Spain-based Towa International, announced on Monday the launch of Pomalidomide Capsules, a generic version of Pomalyst by Celgene (...
Bionpharma and STEERLife's Etravirine tablets approved by US FDA
14 January 2026 - STEERLife, the life sciences division of India-based STEER World, and Bionpharma Inc, a US-based pharmaceutical company, announced on Tuesday that Bionpharma has received Abbreviated...